MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 1,594 patients (estimated)
- Sponsors
- European Myeloma Network
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, Bispecific T Cell Engager (BiTE), B-Cell Maturation Antigen (BCMA), CD3, Maintenance, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2053
- NCT Identifier
- NCT05243797
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.